Atypical and anaplastic meningiomas treated with bevacizumab

@article{Nayak2012AtypicalAA,
  title={Atypical and anaplastic meningiomas treated with bevacizumab},
  author={Lakshmi Nayak and Fabio M. Iwamoto and Jeremy D. Rudnick and Andrew David Norden and Eudocia Quant Lee and Jan Drappatz and Antonio A Omuro and T Kaley},
  journal={Journal of Neuro-Oncology},
  year={2012},
  volume={109},
  pages={187-193}
}
Atypical and anaplastic (WHO Grades II and III) meningiomas are aggressive tumors, and patients often progress despite surgery and radiation. There is no known effective chemotherapeutic option for these patients. Meningiomas have a high expression of vascular endothelial growth factor receptor (VEGFR). We sought to retrospectively study the activity of bevacizumab, which is an anti-angiogenic agent targeting the VEGF pathway in these tumors. This is a retrospective review of WHO Grade II and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
39 Citations
10 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

WHO classification of tumours of the central nervous system, 4th edn

  • DN Louis, H Ohgaki, OD Wiestler, WK Cavenee
  • 2007
Highly Influential
3 Excerpts

Phase II trial of sunitinib (SU011248) for recurrent meningioma

  • TJ Kaley, D Schiff, S Karimi
  • Neurooncology 12(Suppl
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…